ERBB2 and cancer: With HER2 being a known target for treatment resulting in superior outcomes, and with the recent indication of Fam‐trastuzumab deruxtecan for specific HER2‐low cancers, we desired to explore the difference in prognosis between HER2‐negative and HER2‐low at the population level with current standard of care treatment.